Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Posterior Reversible Encephalopathy Syndrome in Pediatric Hematopoietic Stem Cell Transplantation With Beta Major Thalassemia: The Association Between the Pres Occurrence and Class of Beta Major Thalassemia Publisher Pubmed



Jafari L1 ; Behfar M1 ; Tabatabaie S1 ; Karamlou Y1 ; Kashani H2 ; Radmard AR3 ; Mohseni R1 ; Naji P1 ; Ghanbari F1 ; Ashkevari P1 ; Fakhr H1 ; Mohammadi S1 ; Hamidieh AA1
Authors

Source: Clinical Transplantation Published:2024


Abstract

Introduction: Allogeneic hematopoietic stem cell transplantation (HSCT) is the only definitive curative option for β-major thalassemia patients (β-MT). Posterior reversible encephalopathy syndrome (PRES) is a pervasive neurological complication which typically occurs following HSCT. β-MT patients are prone to a higher PRES incidence due to long-term immunosuppression; thus, it is imperative that these patients are closely monitored for PRES after HSCT. Patients and methods: We included 148 pediatric patients with β-MT who underwent HSCT between March 2015 and August 2022 in Children's Medical Center. Patients in this study were divided into two groups. The association between PRES and class of β-MT and other risk factors were assessed and the overall survival rate was determined. Results: Fourteen out of 112 patients (12%) with class I and II β-MT developed PRES. However, PRES occurred in 11 out of 36 patients (30.5%) with β-MT-III. Our results indicated that there was a significant association between class III β-MT and the occurrence of (P =.004). Additionally, acute graft-versus-host disease (aGVHD) occurred in 80% and 44.7% of patients in the PRES and non-PRES groups, respectively (P =.001). The results of the Kaplan-Meier analysis revealed that the 5-year overall survival (OS) was 75.6% in the PRES group versus 95% in the non-PRES group, which was statistically significant (P =.001). Conclusion: Based on our results, pediatric β-MT III patients are at a higher risk of developing PRES. Additionally, pediatric β-MT patients with a history of aGVHD, regardless of disease class, are more likely to develop PRES. Considering these results, PRES has a higher chance of being the etiology of symptoms and should be considered more often in these patients. © 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Other Related Docs
12. Long--Term Free Survival of Two Class Iii Β-Thalassemic Patients After Non-Myeloablative Stem Cell Transplantation, International Journal of Hematology-Oncology and Stem Cell Research (2020)
14. Hematopoietic Sct in Iranian Children 1991-2012, Bone Marrow Transplantation (2015)
16. Hsct in Patients With Hemoglobinopathies, Cardiovascular Considerations in Hematopoietic Stem Cell Transplantation (2024)
18. Covid-19: Neuroimaging Features of a Pandemic, Journal of Neuroimaging (2021)